Search Result
Results for "
Alpha 6 integrin Inhibitors
" in MedChemExpress (MCE) Product Catalog:
5820
Inhibitors & Agonists
429
Biochemical Assay Reagents
434
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-134130
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC50 of 12.9 nM .
|
-
-
- HY-133971
-
|
5α,6α-Epoxycholesterol
|
Liposome
|
Others
|
|
Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.
|
-
-
- HY-133971S
-
-
-
- HY-P9911A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
|
-
-
- HY-48959
-
|
|
Integrin
|
Metabolic Disease
|
|
α7β1 integrin modulator-1 is a potent α7β1 integrin modulator. α7β1 integrin modulator-1 has the potential for the research of muscular dystrophy .
|
-
-
- HY-139702
-
|
|
Integrin
|
Cancer
|
|
α5β1 integrin agonist-1, acting as α5β1 integrin agonist, is able to selectively deliver 5-FU into tumor cells, successfully leading to cancer cell death.
|
-
-
- HY-169330
-
|
|
Drug Metabolite
|
Neurological Disease
Metabolic Disease
|
|
3β,5α,6β-Trihydroxycholanic acid is a metabolite of 3β,5α,6β-Trihydroxycholestane (HY-W010934). 3β,5α,6β-Trihydroxycholanic acid can be used in research related to neurodegenerative diseases associated with lysosomal dysfunction .
|
-
-
- HY-161730
-
-
-
- HY-W342092
-
|
|
Others
|
|
|
1,3,4,6-Tetrachloro-3α,6α-diphenylglycouril is a chemical agent that has the property of inhibiting enzyme activity in organisms. 1,3,4,6-Tetrachloro-3α,6α-diphenylglycouril is used as a potential anti-tumor agent in compound development. 1,3,4,6-Tetrachloro-3α,6α-diphenylglycouril has the effect of regulating cell signaling pathways and can be used to study cell biology. 1,3,4,6-Tetrachloro-3α,6α-diphenylglycouril is considered to be a potent compound that can exert biological activity under specific conditions.
|
-
-
- HY-W726076
-
|
|
Biochemical Assay Reagents
|
Others
|
|
3α,6α-Mannopentaose is a class of biochemical reagents used in glycobiology research. Glycobiology studies the structure, synthesis, biology, and evolution of sugars. It involves carbohydrate chemistry, enzymology of glycan formation and degradation, protein-glycan recognition, and the role of glycans in biological systems. This field is closely related to basic research, biomedicine, and biotechnology .
|
-
-
- HY-W010934S
-
-
-
- HY-159179
-
|
|
Integrin
|
Inflammation/Immunology
|
|
α4 integrin receptor antagonist 3 (Compound 11) is an orally active α4integrin receptor antagonist. α4 integrin receptor antagonist 3 can inhibit the adhesion of K562 cells mediated by the interaction between α4β1/VCAM-1 and α4β7/MAdCAM-1, with IC50 values of 130 nM and 2 nM, respectively. α4 integrin receptor antagonist 3 has the potential to be used in the study of dextran sulfate sodium (DSS) colitis mouse model .
|
-
-
- HY-150857S
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
Thymine-α,α,α,6-d4 Glycol (mixture of diastereomers)-d4 is the deuterium labeled Thymine-α,α,α,6-d4 Glycol (mixture of diastereomers)[1].
|
-
-
- HY-P1868
-
|
DGEA peptide
|
Integrin
|
Infection
|
|
α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
|
-
-
- HY-N9175
-
|
|
Others
|
Others
|
|
4α,6α-Dihydroxyeudesm-11(13)-en-12,8β-olide is a Sesquiterpenoids product that can be isolated from the herbs of Chloranthus elatior .
|
-
-
- HY-N1202
-
|
Sitostane-3β,5α,6β-triol
|
Others
|
Others
|
|
Sitostanetriol (Sitostane-3β,5α,6β-triol) is a steroid isolated from Casearia membranacea (Flacourtiaceae) .
|
-
-
- HY-N1810
-
|
3α,6β-Ditigloyloxytropan-7β-ol
|
Others
|
Others
|
|
Ditigloylteloidine (3α,6β-Ditigloyloxytropan-7β-ol) is a Sesquiterpenoids product that can be isolated from the herbs of Eupatorium chinense var. tozanense. .
|
-
-
- HY-P1868A
-
|
DGEA peptide TFA
|
Integrin
|
Others
|
|
α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
|
-
-
- HY-N10639
-
|
|
Others
|
Others
|
|
(1α,2α,6β,8α,9α)-1,2,6,8,12-Pentakis(acetyloxy)-9-(benzoyloxy)dihydro-β-agarofuran is a sesquiterpene polyol ester. (1α,2α,6β,8α,9α)-1,2,6,8,12-Pentakis(acetyloxy)-9-(benzoyloxy)dihydro-β-agarofuran can be used for the research of various biochemical .
|
-
-
- HY-W010934
-
|
|
Biochemical Assay Reagents
|
Others
|
|
3β,5α,6β-Trihydroxycholestane is a steroid that occurs naturally in the body and is also found in certain foods. It belongs to a class of compounds known as cholestanes, which are closely related to the better known cholesterol. This particular compound is formed from cholesterol through a series of enzymatic reactions in the liver and other organs. It has been studied for its potential health benefits, including its ability to reduce inflammation and oxidative stress in the body. Some research suggests that it may also play a role in regulating blood sugar levels and improving insulin sensitivity. Despite these potential benefits, 3β,5α,6β-Trihydroxycholestane is not widely used as a supplement or medicine due to its relatively low content, focus on natural resources and limited research. However, researchers continue to investigate its potential uses and effects on human health.
|
-
-
- HY-145363
-
|
|
Integrin
|
Cancer
|
|
Sulodexide (pIC50 = 8.2 nM) selectively binds to the αvβ5 integrin in K562 and A549 cell lines and exhibits a significant inhibitory effect .
|
-
-
- HY-146767S
-
-
-
- HY-P9911
-
|
Anti-Human lymphocyte α4β7 integrin, Humanized Antibody
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
|
-
-
- HY-156521
-
|
|
Integrin
|
Others
|
|
αvβ1 integrin-IN-2 (compound 32) is a potent inhibitor of integrins ανβ1 and α5β1 with IC50s of 0.9 nM，and 33 nM，respectively. αvβ1 integrin-IN-2 also inhibits other integrins with ，，IC50s of 380 nM (ανβ3)，280 nM (ανβ5)，230 nM (ανβ6)，87 nM (ανβ8)，respectively，in SPRA assay .
|
-
-
- HY-P2532
-
|
|
Integrin
|
Others
|
|
Integrin Binding Peptide is derived by fibronectin. Integrin Binding Peptide can be used for PEG hydrogel preparation .
|
-
-
- HY-N12135
-
|
|
Others
|
Cancer
|
|
15α-Hydroxy-20-oxo-6,7-seco-ent-kaur-16-en-1,7α(6,11α)-diolide (compound 2) is an enantio-kaurene diterpenoid (ent -kaurene diterpenoid), which can be isolated from Rubescens rubescens. 15α-Hydroxy-20-oxo-6,7-seco-ent-kaur-16-en-1,7α(6,11α)-diolide has cellular activity against EC-1, U87, A549, MCF-7 and HeLa cell lines Toxicity, IC50s are 37.69 μM, 79.362 μM, 80.07 μM, 197.35 μM, 462.13 μM, and 180.09 μM respectively .
|
-
-
- HY-136214
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
R-BC154 acetate is a selective fluorescent α9β1 integrin antagonist. R-BC154 acetate acts as a useful high affinity, activation dependent integrin probe, which can be used to investigate α9β1 and α4β1 integrin binding activity .
|
-
-
- HY-123802
-
|
|
Integrin
|
Cancer
|
|
BIO7662 is a specific α4β1 antagonist. BIO7662 can be used to study α4β1 integrin-ligand interactions .
|
-
-
- HY-P6022
-
|
|
Integrin
|
Others
|
|
G4RGDSP, Integrin-binding peptide is a cell integrin-binding peptide that targets integrin receptors. G4RGDSP, integrin-binding peptide is coupled to alginate to increase the viability of cells in the scaffold. G4RGDSP, integrin-binding peptide can be used as an extrudable carrier for chondrocyte delivery for the study of 3D printing technology
|
-
-
- HY-150124
-
|
|
Integrin
|
Cancer
|
|
K34c is a potent and selective α5β1 integrin antagonist. K34c can be used for glioblastoma research .
|
-
-
- HY-130119
-
|
|
Integrin
|
Cancer
|
|
Integrin-IN-2 (compound 39) is an orally bioavailable pan αv integrin inhibitor. Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC50 values of 7.8, 8.4, 8.4 and 7.4, respectively .
|
-
-
- HY-129453
-
|
|
Integrin
|
Inflammation/Immunology
|
|
BOP sodium is a potent and selective dual α9β1/α4β1 integrin inhibitor with Kd values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors. BOP sodium has little inhibitory activity on α4β7, α1β1, α2β1, and α5β1, αIIBβ3 integrins .
|
-
-
- HY-18668
-
|
|
Integrin
|
Cancer
|
|
Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent.
|
-
-
- HY-100445
-
-
-
- HY-100445A
-
-
-
- HY-153807
-
-
-
- HY-P1654
-
|
|
Integrin
|
Cancer
|
|
A20FMDV2 is a selective αvβ6 integrin inhibitor (IC50: 3 nM), with an activity 1,000-fold more selective for αvβ6 than for other RGD-directed integrins (αvβ3, αvβ5, and α5β1). A20FMDV2 can be derived from the foot-and-mouth disease virus. A20FMDV2 can be radiolabeled for the PET imaging of αvβ6 integrin-positive tumors .
|
-
-
- HY-P10417
-
|
|
Integrin
|
Others
Cancer
|
|
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development .
|
-
-
- HY-15770
-
|
|
Integrin
|
Inflammation/Immunology
|
|
TR-14035 is a orally active dual α4β7/α4β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases .
|
-
-
- HY-P3523
-
|
|
Integrin
|
Others
|
|
KGDS is synthetic peptides, targeting integrin GPIIb-IIIa located on the membrane of human activated platelets. Amino acid sequence: Lys-Gly-Asp-Ser .
|
-
-
- HY-P990207
-
|
|
Integrin
|
Others
|
|
Anti-Mouse/Human Integrin β7 Antibody (FIB504) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human Integrin β7.
|
-
-
- HY-118335
-
|
SZL 49
|
Adrenergic Receptor
|
Neurological Disease
|
|
Prazobind (SZL 49), a prazosin analog, is a potent alpha 1-adrenoceptor blocker. Prazobind competes for alpha 1-adrenoceptor binding sites with a similar potency (IC50=1 nM) in tissues enriched in both the alpha 1A (hippocampus) and alpha 1B (liver) subtypes .
|
-
-
- HY-P3533
-
|
|
Integrin
|
Cardiovascular Disease
|
|
EILEVPST is a recombinant human fibronectinderived low-molecular-weight peptide fragment. EILEVPST can promote cell type-specific α4 integrin-mediated adhesion. EILEVPST can be used for the research of thrombogenesis .
|
-
-
- HY-123349
-
|
|
Drug Metabolite
|
Cardiovascular Disease
|
|
5α-Hydroxy-6-keto cholesterol is major metabolite of β-epoxide (5α,6β-epoxycholesterol) during direct exposure of intact cultured human bronchial epithelial cells (16-HBE) to ozone. 5α-Hydroxy-6-keto cholesterol inhibits cholesterol synthesis with an IC50 of 350 nM .
|
-
-
- HY-P9984
-
|
rhuMAb Beta7; RG7413; PRO145223
|
Integrin
|
Cancer
|
|
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
|
-
-
- HY-P99184
-
|
|
Integrin
|
Infection
Inflammation/Immunology
Cancer
|
|
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
|
-
-
- HY-108831A
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
|
-
-
- HY-70073
-
-
-
- HY-P1930A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Risuteganib hydrochloride is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .
|
-
-
- HY-P1930
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .
|
-
- HY-P0178
-
|
|
Integrin
|
Inflammation/Immunology
|
|
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
|
-
- HY-P0023
-
|
|
Integrin
|
Cancer
|
|
Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
|
-
- HY-P0178A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
|
-
- HY-16141
-
|
EMD 121974
|
Integrin
Autophagy
Apoptosis
STAT
PD-1/PD-L1
|
Cancer
|
|
Cilengitide (EMD 121974) is a potent integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers .
|
-
- HY-P0023A
-
|
|
Integrin
|
Cancer
|
|
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
|
-
- HY-P0322
-
|
EMD 56574
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
|
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
|
-
- HY-P0322A
-
|
EMD 56574 TFA
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
|
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .
|
-
- HY-139137
-
|
AGGC
|
DNA Methyltransferase
Integrin
|
Cancer
|
|
N-Acetyl-S-geranylgeranyl-L-cysteine is a Methyltransferase inhibitor. N-Acetyl-S-geranylgeranyl-L-cysteine inhibits beta 2 integrin-induced actin polymerization with an IC50 of 45 nM .
|
-
- HY-111413
-
|
|
Integrin
|
Cancer
|
|
c(phg-isoDGR-(NMe)k) is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM .
|
-
- HY-111413A
-
|
|
Integrin
|
Cancer
|
|
c(phg-isoDGR-(NMe)k) TFA is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM .
|
-
- HY-P3732
-
|
|
Integrin
|
Cancer
|
|
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .
|
-
- HY-107588
-
TC-I 15
1 Publications Verification
|
Integrin
|
Cardiovascular Disease
|
|
TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
|
-
- HY-W436495
-
|
6,15-Diketo-13,14-dihydro-PGF1α
|
Drug Metabolite
|
Metabolic Disease
|
|
6,15-Diketo-13,14-dihydro prostaglandin F1α (6,15-Diketo-13,14-dihydro-PGF1α) is a metabolite of prostacyclin (PGI2). 6,15-Diketo-13,14-dihydro prostaglandin F1α enhances intracellular cAMP and cholesterol metabolism in bovine arterial smooth muscle cells .
|
-
- HY-P3522
-
|
|
Integrin
|
Cancer
|
|
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion .
|
-
- HY-P2267
-
LDV
1 Publications Verification
|
Integrin
|
Others
|
|
LDV is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells .
|
-
- HY-P3522A
-
|
|
Integrin
|
Cancer
|
|
REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV TFA can be used for the research of cell adhesion .
|
-
- HY-152170
-
|
|
nAChR
|
Neurological Disease
|
|
bPiDI is a novel selective α6β2 nicotinic receptor antagonist. bPiDI inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .
|
-
- HY-106416
-
-
- HY-124290
-
|
AJM300
|
Integrin
|
Inflammation/Immunology
|
Carotegrast methyl (AJM300) is an orally active and selective α4 integrin antagonist. HCA2969, an active metabolite of Carotegrast methyl, is a specific and dual α4β1/α4β7 integrin antagonist. Carotegrast methyl prevents the development of colitis in mice .
|
-
- HY-124290A
-
|
AJM300 hydrochloride
|
Integrin
|
Inflammation/Immunology
|
Carotegrast methyl (AJM300) hydrochloride is an orally active and selective α4 integrin antagonist. HCA2969, an active metabolite of Carotegrast methyl hydrochloride, is a specific and dual α4β1/α4β7 integrin antagonist. Carotegrast methyl hydrochloride prevents the development of colitis in mice .
|
-
- HY-P99291
-
|
LM 609; MEDI 523; Anti-αvβ3 integrin Recombinant Antibody
|
Integrin
|
Cancer
|
|
Etaracizumab (LM 609) is an αvβ3 integrin IgG1 monoclonal antibody. Etaracizumab inhibits angiogenesis and melanoma tumor growth. Etaracizumab can be used to research anticancer .
|
-
- HY-124110
-
|
|
nAChR
|
Neurological Disease
|
|
TC299423 is an orally active, brain-penetrant, selective and potent agonist for α6β2 ∗ and α4β2 ∗ nicotinic acetylcholine receptors (nAChRs) with anxiolytic and antinociceptive properties. TC299423 acts primarily through α6β2 ∗ nAChRs that are implicated in the anxiolytic effects of nicotine. TC299423 elicits reward-related behavior mediated through α6β2 ∗ nAChRs in hypersensitive α6L90’S mice. TC299423 elicits dopamine release and dose not suppress nicotine self-administration in rats. TC299423 is proming for rasearch of addiction and Parkinson’s disease .
|
-
- HY-14571
-
E7820
4 Publications Verification
ER68203-00
|
Molecular Glues
Integrin
|
Cancer
|
|
E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits rat aorta angiogenesis with an IC50 of 0.11 μg/ml. E7820 modulates α-1, α-2, α-3, and α-5 integrin mRNA expression. Antiangiogenic and antitumor activity .
|
-
- HY-P4896
-
|
|
Integrin
|
Cancer
|
|
FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an integrin inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis .
|
-
- HY-110142
-
|
CC4
|
nAChR
|
Neurological Disease
|
|
Thermopsidine (CC4) is a selective partial agonist at α4β2/α6β2 nAChR with EC50 values of 2.2 μM target α4β2 .
|
-
- HY-115677
-
|
|
Integrin
DYRK
|
Cancer
|
|
ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel (HY-B0011) in orthotopic LCC6 model .
|
-
- HY-14857
-
-
- HY-160959
-
|
|
nAChR
|
Neurological Disease
|
|
AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with Ki of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP +. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB) .
|
-
- HY-112910
-
|
|
HSP
|
Inflammation/Immunology
Cancer
|
|
Grp94 Inhibitor-1 is a potent, selective Grp94 inhibitor with an IC50 value of 2 nM, and over 1000-fold selectivity to Grp94 against Hsp90α .
|
-
- HY-P1613
-
|
Cyclo(RGDfV); C(RGDfV)
|
Integrin
Apoptosis
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .
|
-
- HY-120337
-
|
|
Others
|
Cancer
|
|
V-11-0711 is a potent and selective choline kinase alpha (ChoKα) inhibitor with an IC50 of 20 nM. V-11-0711 causes a reversible growth arrest in HeLa cells .
|
-
- HY-163360
-
|
|
PI3K
|
Cancer
|
|
PI3Kα-IN-19 (Compound 1) is a PI3Kα inhibitor with a targeted binding site at the p110α catalytic subunit. PI3Kα is one of the most common dysregulated kinases used in cancer research .
|
-
- HY-P990643
-
|
|
Integrin
|
Inflammation/Immunology
|
|
OS-2966 is a humanized antibody expressed in CHO cells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-106769
-
-
- HY-106769C
-
|
GR50360 hydrochloride
|
Adrenergic Receptor
|
Neurological Disease
|
|
Fluparoxan hydrochloride is an orally active, selective and competitive alpha 2-adrenoceptor antagonist. Fluparoxan hydrochloride is an anti-depressant agent .
|
-
- HY-P5038
-
|
c(GRGDSP)
|
Integrin
|
Cancer
|
|
Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) is a synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin expressed on Caco-2 cells .
|
-
- HY-P1613A
-
|
Cyclo(RGDfV) TFA; C(RGDfV) TFA
|
Integrin
Apoptosis
|
Cancer
|
|
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .
|
-
- HY-W008859
-
Tetrac
1 Publications Verification
Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid
|
Integrin
Endogenous Metabolite
|
Cancer
|
|
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities .
|
-
- HY-107674
-
|
|
nAChR
|
Neurological Disease
|
|
bPiDDB is a potent nAChR antagonist. bPiDDB potently (IC50=2 nM) inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .
|
-
- HY-164768
-
|
|
Integrin
|
Cancer
|
|
LT25 (compound 17) is a agonist of α5β1 integrin with EC50 value of 9.9 nM .
|
-
- HY-P99560
-
|
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
|
-
- HY-P3448
-
|
CEND-1; iRGD; LSTA1
|
Integrin
Complement System
|
Cancer
|
|
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .
|
-
- HY-P1188
-
|
|
Integrin
|
Cancer
|
|
LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC can be used to detect α4β1 integrin affinity .
|
-
- HY-162518
-
|
|
Kinesin
Microtubule/Tubulin
|
Cancer
|
|
Eg5-IN-3 (5) is an Eg5 inhibitor that targets the novel allosteric pocket (α4/α6/L11). Eg5-IN-3 (5) causes tubulin assembly distortion with irregular morphology, resulting in a typical mitotic arrest similar to Monastrol (HY-101071A) .
|
-
- HY-137561A
-
|
PLN-74809 hydrochloride
|
Integrin
|
Inflammation/Immunology
|
|
Bexotegrast hydrochloride (PLN-74809 hydrochloride) is a small molecule dual selective inhibitor with activity targeting αVβ1 and αVβ6. Bexotegrast hydrochloride is used for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast hydrochloride inhibits the activation of TGF-β1 by blocking the function of these integrins, thereby preventing the growth of fibrous tissue in the lungs and bile ducts .
|
-
- HY-100554
-
|
|
Adrenergic Receptor
5-HT Receptor
|
Cardiovascular Disease
|
|
BMY 7378 is a selective antagonist of α1D-adrenoceptor (α1D-AR). BMY 7378 binds to membranes expressing the cloned rat α1D-AR with a >100-fold higher affinity (Ki=2 nM) than binding to either the cloned rat α1A-AR (Ki=800 nM) or the hamster α1B-AR (Ki=600 nM). BMY 7378 is a 5-HT1A receptor partial agonist .
|
-
- HY-P99333
-
|
M200; Eos 200-4
|
Integrin
|
Cardiovascular Disease
Cancer
|
|
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
|
-
- HY-113097
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
3α,7α-Dihydroxycoprostanic acid is an endogenous metabolite. 3α,7α-Dihydroxycoprostanic acid, a bile acid, is the precursor to chenodeoxycholic acid .
|
-
- HY-75385
-
|
CDP323; UCB1184197
|
Integrin
|
Inflammation/Immunology
|
|
Zaurategrast ethyl ester (CDP323), the ethyl ester proagent of CT7758 , is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders .
|
-
- HY-13535A
-
|
ATN-161 TFA salt
|
Integrin
|
Cancer
|
|
ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
|
-
- HY-P0031
-
|
|
Integrin
|
Others
|
|
Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.
|
-
- HY-13535
-
|
|
Integrin
|
Cancer
|
|
ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
|
-
- HY-N3994
-
|
|
Others
|
Others
|
|
16α,17α-Epoxyprogesterone is an important steroid, serving as an intermediate for many hormonal drugs such as Hydrocortisone (HY-N0583) and Megestrol (HY-B1834). 16α,17α-Epoxyprogesterone can further biotransform into another significant intermediate, 11α-hydroxy-16α,17α-epoxyprogesterone, to manufacture additional compounds .
|
-
- HY-P1188A
-
|
|
Integrin
|
Cancer
|
|
LDV-FITC TFA, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC TFA binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC TFA can be used to detect α4β1 integrin affinity .
|
-
- HY-126402
-
|
|
Integrin
|
Cancer
|
|
Arg-Gly-Asp (RGD) is a synthetic peptide corresponding to the cell adhesion sequence for the integrins αVβ1, αVβ3, αVβ5, αVβ6, αVβ8, α8β1, and α5β1. It is a component of radioligands and peptidomimetics that have been used in the study of integrin expression and activity in vivo.
|
-
- HY-75385A
-
|
CDP323 sulfate; UCB1184197 sulfate
|
Integrin
|
Inflammation/Immunology
|
|
Zaurategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester proagent of CT7758 , is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders .
|
-
- HY-107850A
-
|
Allopregnanediol
|
GnRH Receptor
|
Endocrinology
|
|
5α-Pregnane-3α,20α-diol (Allopregnanediol) is a derivative of progesterone and is one of the various steroids secreted by the ovaries of rats. 5α-Pregnane-3α,20α-diol can significantly stimulate the release of luteinizing hormone (LH) in castrated rats that have been pre-treated with estrogen, while simultaneously inhibiting the secretion of follicle-stimulating hormone (FSH) .
|
-
- HY-107589A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM). BIO5192 hydrate selectively binds to α4β1 (IC50=1.8 nM) over a range of other integrins. BIO5192 hydrate results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .
|
-
- HY-107589
-
BIO5192
1 Publications Verification
|
Integrin
|
Inflammation/Immunology
|
|
BIO5192 is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM). BIO5192 selectively binds to α4β1 (IC50=1.8 nM) over a range of other integrins. BIO5192 results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .
|
-
- HY-E70297
-
|
MGAT4A
|
Endogenous Metabolite
|
Cancer
|
|
N-Acetylglucosaminyltransferase IVa (MGAT4A) is a glycosyltransferase that can enhance the migration, invasion, and adhesion abilities of cancer cells, and increase β1,4GlcNAc branched glycans on integrin β1 (ITGB1), a tumor-associated glycoprotein closely related to cell motility .
|
-
- HY-P990667
-
|
|
Integrin
|
Inflammation/Immunology
|
|
STX-100 is a humanized antibody expressed in CHO cells, targeting Integrin aVb6 (ITGAV & ITGB6). STX-100 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.12 kDa. The isotype control for STX-100 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-113097S1
-
-
- HY-147423
-
-
- HY-113097S
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Others
|
|
3α,7α-Dihydroxycoprostanic acid-d3 is the deuterium labeled 3α,7α-Dihydroxycoprostanic acid (HY-113097) . 3α,7α-Dihydroxycoprostanic acid is an endogenous metabolite. 3α,7α-Dihydroxycoprostanic acid, a bile acid, is the precursor to chenodeoxycholic acid .
|
-
- HY-108831
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
|
-
- HY-15536A
-
|
GRT6005 (1α,4α)stereoisomer
|
Opioid Receptor
|
Neurological Disease
|
|
Cebranopadol ((1α,4α)stereoisomer) is a stereoisomer of cebranopadol. Cebranopadol is a potent agonist activity on ORL-1.
|
-
- HY-138542
-
|
|
Integrin
|
Inflammation/Immunology
|
|
RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. Antiinflammatory activity .
|
-
- HY-137393
-
-
- HY-146225
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-2 (compound 5) is a potent α-amylase and α-glucosidase dual inhibitor with IC50 values of 13.02, 13.09 µM for α-amylase and α-glucosidase, respectively. α-Amylase/α-Glucosidase-IN-2 has the potential for the research of diabetic complications .
|
-
- HY-N2853
-
|
α-Tocopherylquinone
|
Others
|
Cancer
|
|
D-α-Tocopherylquinone (α-Tocopherylquinone) is a quinone, can be isolated from Phaeodactylum tricornutum. D-α-Tocopherylquinone is a oxidation product of α-Tocopherol (vitamin E). D-α-Tocopherylquinone can act as an anticoagulant and as an antioxidant .
|
-
- HY-116030
-
|
|
Integrin
|
Metabolic Disease
|
|
JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha(V)beta(3) and alpha(V)beta(5), respectively. JNJ-26076713 inhibits retinal neovascularization .
|
-
- HY-147711
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-1 (compound 33) is a potent α-amylase/α-glucosidase inhibitor with IC50s of 2.01, 2.09 µM for α-amylase and α-glucosidase, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has the potential of anti hyperglycemia .
|
-
- HY-131368
-
|
Tre6P potassium
|
Endogenous Metabolite
|
Others
|
|
α,α-Trehalose 6-phosphate (Tre6P) potassium is an endogenous metabolite. α,α-Trehalose 6-phosphate is a 6-phosphate derivative of α,α′-trehalose. α,α-Trehalose 6-phosphate is rapidly converted to the pathway end product, α,α′-trehalose, through the action of Tre6P phosphatase (T6PP) .
|
-
- HY-131368A
-
|
Tre6P
|
Endogenous Metabolite
|
Others
|
|
α,α-Trehalose 6-phosphate (T6P) is an endogenous metabolite. α,α-Trehalose 6-phosphate is a 6-phosphate derivative of α,α′-trehalose. α,α-Trehalose 6-phosphate is rapidly converted to the pathway end product, α,α′-trehalose, through the action of Tre6P phosphatase (T6PP) .
|
-
- HY-N1163
-
-
- HY-19667
-
|
DPC 333
|
TNF Receptor
|
Inflammation/Immunology
|
|
BMS-561392 is a TNF alpha-converting enzyme (TACE) inhibitor. BMS-561392 is also an ADAM17 blocker. BMS-561392 can be used for research of inflammatory bowel disease .
|
-
- HY-N9487
-
|
(-)-α-Phellandrene
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
(R)-(-)-α-Phellandrene ((-)-α-Phellandrene) is an the (R)-(-)-stereoisomer of α-phellandrene. α-phellandrene is an orally active cyclic monoterpene that attenuates inflammatory response, and induces DNA damage .
|
-
- HY-122247
-
|
|
Kinesin
|
Cancer
|
|
PVZB1194 is a biphenyl-type
inhibitor of Kinesin-5 ATPase activity that binds to the α4/α6 site of the motor domain in a nucleotide competitive manner. PVZB1194 has an IC50 of 0.12 μM for KSP ATPase. PVZB1194 induces mitotic arrest with the formation of a monopolar spindle, and inhibits HeLa cells proliferatio (IC50: 5.5 μM). PVZB1194 can be used in the study of tumors .
|
-
- HY-162169
-
|
|
Amylases
Glycosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-8 (Compound 7p) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 10.19 and 10.33 μM, respectively. α-Amylase/α-Glucosidase-IN-8 has good anti-oxidant activity(IC50 = 14.93 μM). α-Amylase/α-Glucosidase-IN-8 can be used for the research of diabetes .
|
-
- HY-162390
-
|
|
Amylases
Glycosidase
|
Endocrinology
|
|
α-Amylase/α-Glucosidase-IN-11 (Compound 5d) is a isoxazolidine-isatin hybrid with significant antidiabetic activity. α-Amylase/α-Glucosidase-IN-11 competitively inhibits α-amylase (IC50 = 30.39 μM) and α-glucosidase (IC50 = 65.1 μM), two key digestive enzymes. α-Amylase/α-Glucosidase-IN-11 does not cross the blood-brain barrier .
|
-
- HY-137561
-
|
PLN-74809
|
Integrin
|
Inflammation/Immunology
|
|
Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung .
|
-
- HY-161469
-
-
- HY-154972
-
|
|
Glycosidase
Amylases
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an α-Amylase/α-Glucosidase dual inhibitor, with IC50s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus .
|
-
- HY-149557
-
|
|
Glycosidase
Amylases
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-5 (compound 4l) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50s of 5.96 μM and 1.62 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .
|
-
- HY-155241
-
|
|
Glycosidase
Amylases
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-4 (compound 5) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50s of 0.15 μM and 1.10 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .
|
-
- HY-156380
-
|
|
Amylases
Glycosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase-IN-6 exhibits anti-hyperglycemic activities .
|
-
- HY-162673
-
|
|
Amylases
Glycosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-16 (compound 15) is a potent dual inhibitor of α-amylase and α-Glucosidase with IC50 values of 0.8 and 1.2 μM, respectively. α-Amylase/α-Glucosidase-IN-16 can be used in the study of diabetes mellitus (DM) .
|
-
- HY-14951
-
|
SB 683699
|
Integrin
|
Neurological Disease
|
|
Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity .
|
-
- HY-B0892S
-
-
- HY-N10564
-
|
|
P-glycoprotein
|
Cancer
|
|
8α,9α-Epoxycoleon-U-quinone (compound 3) is a p-glycoprotein (P-gp) regulator that is selective for cancer cells (SI=2.0). 8α,9α-Epoxycoleon-U-quinone effectively inhibits P-gp activity in NCI-H460/R cells. 8α,9α-Epoxycoleon-U-quinone also reverses the resistance of cancer cells to Doxorubicin (DOX) (HY-15142A) and enhances the anticancer effect of DOX .
|
-
- HY-W127508
-
|
|
Biochemical Assay Reagents
|
Others
|
|
α,α'-Dilaurin is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-133966
-
|
5α-Cholestane-3β,6α-diol
|
Reactive Oxygen Species
|
Others
|
|
6α-Hydroxy-5α-cholestane (5α-Cholestane-3β,6α-diol) is an oxysterol that promotes the production of superoxide anions in SK-N-BE cells at concentrations of 50 μM and 100 μM .
|
-
- HY-162036
-
|
|
Glycosidase
Amylases
Cholinesterase (ChE)
|
Neurological Disease
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-7 (Compound 3f) is a competitive α-glucosidase and α-amylase enzyme inhibitor with IC50 values of 18.52 and 20.25 µM, respectively. α-Amylase/α-Glucosidase-IN-7 can also effectively inhibit AChE and BChE, with IC50 values of 9.25 and 10.06 µM respectively. α-Amylase/α-Glucosidase-IN-7 can be used in diabetes and Alzheimer’s research .
|
-
- HY-N2514
-
|
α-D-Lactose
|
Others
|
Others
|
|
α-Lactose (α-D-Lactose) is the major sugar present in milk. Lactose exists in the form of two anomers, α and β. The α form normally crystallizes as a monohydrate .
|
-
- HY-W399297
-
|
7α,12α-Dihydroxycholanoic acid
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Isodeoxycholic acid (7α,12α-Dihydroxycholanoic acid) is the 3β-epimer of ursodeoxycholic acid. Isodeoxycholic acid has the effect on choleresis and liver biochemistry .
|
-
- HY-130529
-
|
OH-α-Pyrrolidinovalerophenone TFA
|
Endogenous Metabolite
|
Metabolic Disease
|
|
OH-α-PVP (OH-α-Pyrrolidinovalerophenone ) TFA is a metabolite of α-pyrrolidinovalerophenone. α-pyrrolidinovalerophenone is a synthetic stimulant of the cathinone class .
|
-
- HY-P5859
-
|
α-PMTX
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
α-Pompilidotoxin (α-PMTX) is a neurotoxin that can be obtained from the venom of Anoplius safnariensis. α-Pompilidotoxin reversibly and dose-dependently enhances excitatory postsynaptic currents (EPSCs). α-Pompilidotoxin is a useful tool in the field of neuroscience research .
|
-
- HY-170056
-
-
- HY-14189
-
|
R-411
|
Integrin
|
Inflammation/Immunology
|
|
Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment .
|
-
- HY-114656
-
|
Dihydroprostaglandin F1α
|
Others
|
Endocrinology
|
|
Dihydro-PGF1α is a potential metabolite of PGF1α .
|
-
- HY-N1467
-
|
(S)-α-Terpineol
|
Others
|
Others
|
|
(-)-α-Terpineol ((S)-α-Terpineol), a monoterpene compound, is one of compounds in Melaleuca alternifolia. (-)-α-Terpineol has antioxidant and anti-inflammatory activities .
|
-
- HY-P10038
-
|
Myr-FEEERA-OH
|
Integrin
|
Infection
|
|
mP6 (Myr-FEEERA-OH) is a myristoylated peptide. mP6 inhibits the interaction of Gα13 with integrin β3 without disrupting talin-dependent integrin function. mP6 can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells .
|
-
- HY-P9970A
-
|
Avakine (Anti-TNF-α); CT-P13 (Anti-TNF-α)
|
TNF Receptor
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
|
-
- HY-162634
-
|
|
Amylases
Glycosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-15 (compound 6C) is an oral bioactive inhibitor of α-Glucosidase and α-amylase, with the IC50s of 21 μM and 61 μM, respectively .
|
-
- HY-N0611
-
|
α-Boswellic acid
|
Others
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
alpha-Boswellic acid (α-Boswellic acid) is an orally active pentacyclic triterpenoid compound that can be extracted from frankincense. alpha-Boswellic acid has anti-inflammatory and antitumor activities. alpha-Boswellic acid can be used in Alzheimer's disease (AD) research .
|
-
- HY-120874
-
|
|
GABA Receptor
|
Neurological Disease
|
|
PF-06372865 is an orally active, α2/α3/α5 subtype-selective GABAA positive allosteric modulator (PAM). PF-06372865 is a high affinity ligand at GABAA receptors containing α1/α2/α3/α5 subunits (Kis of 2.9 nM, 21 nM, 134 nM for α2, α1 PAM, α2 PAM, respectively), with low affinity for α4/α6 subunits. PF-06372865 can across the blood-brain barrier (BBB). PF-06372865 has anxiolytic activity and has the potential for epilepsy .
|
-
- HY-N8459
-
|
α-CBD
|
EBV
|
Cancer
|
|
α-Cembrenediol is a potent inhibitor of EBV.α-Cembrenediol inhibits the early antigen of the Epstein-Bar virus. α-Cembrenediol also has anti-tumour activity .
|
-
- HY-115854
-
|
|
GABA Receptor
|
Neurological Disease
|
|
Ro 15-1310 is an imidazobenzodiazepine that exhibits high affinity and selectivity for alpha 5-containing GABAA receptors. Ro 15-1310 is promising for research of convulsions .
|
-
- HY-N9960
-
-
- HY-N0176A
-
|
α-Dihydroqinghaosu; α-Artenimol
|
Parasite
|
Infection
|
|
α-Dihydroartemisinin is a natural product that can be found in artemisinin. α-Dihydroartemisinin also shows antimalarial activity .
|
-
- HY-N2766
-
|
|
Others
|
Others
|
|
8alpha-Hydroxy-alpha-gurjunene is a Sesquiterpenoids product that can be isolated from the herbs of Sarcandra glabra .
|
-
- HY-161355
-
|
|
Amylases
Glycosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-9 (compound 5h) is a dual inhibitor for both α-amylase (IC50 = 16.4 μM) and α-glucosidase (IC50 = 31.6 μM) enzymes .
|
-
- HY-133966S
-
-
- HY-162373
-
|
|
Amylases
Glycosidase
P-glycoprotein
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC50: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .
|
-
- HY-150536
-
|
|
HIV
HIV Protease
|
Infection
|
|
EP39 is a potent HIV-1 maturation inhibitor. EP39 interacts with the SP1 domain of Gag. EP39 decreases the dynamics of CA-SP1 junction, by binding to the QVT motif of the SP1 domain, and perturbs the natural coil-helix equilibrium on both sides of the SP1 domain by stabilizing the transient alpha helical structure. EP39 acts by arresting maturation of HIV-1 thereby blocking its infectivity .
|
-
- HY-P99447
-
|
|
Bacterial
|
Infection
|
|
Atidortoxumab is a human IgG1κ monoclonal antibody that targets Staph aureus alpha toxin .
|
-
- HY-110208
-
BRD9876
1 Publications Verification
|
Kinesin
Microtubule/Tubulin
|
Cancer
|
|
BRD9876 is the “rigor” inhibitor that locks kinesin-5 (Eg5) in a state with enhanced microtubules (MTs) binding, leading to bundling and stabilization of MTs. BRD9876 interacts with the tyrosine 104 residue that is part of the α4-α6 allosteric binding pocket. BRD9876 specifically targets microtubule-bound Eg5 and selectively inhibits myeloma over CD34 cells. BRD9876 has the potential for multiple myeloma (MM) research .
|
-
- HY-149483
-
|
|
nAChR
|
Neurological Disease
|
|
CVN417 is an orally active α6 subunit-containing nAChR antagonist, modulating phasic dopaminergic neurotransmission in an impulse-dependent manner. CVN417 inhibits Ca(2+) effluents mediated by nAChR subunits with IC50s of 0.086 μM (α6), 2.56 μM (α3) and 0.657 μM (α4), respectively. CVN417 attenuates resting tremor in Rodent models, displays the potential to improve movement dysfunction, in conditions such as Parkinson's disease .
|
-
- HY-B0135R
-
|
|
NKCC
GABA Receptor
|
Metabolic Disease
Cancer
|
|
Furosemide (Standard) is the analytical standard of Furosemide. This product is intended for research and analytical applications. Furosemide is a potent and orally active inhibitor of Na +/K +/2Cl - (NKCC) cotransporter, NKCC1 and NKCC2 . Furosemide is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema .
|
-
- HY-129953S1
-
-
- HY-162635
-
|
|
Amylases
Glycosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-14 (compound 6E) is an oral bioactive inhibitor of α-amylase and α-glucosidase, with the IC50s of 45.53 μM and 27.73 μM, respectively .
|
-
- HY-163439
-
|
|
Amylases
Glycosidase
|
Metabolic Disease
|
|
α-Amylase/α-Glucosidase-IN-12 (compound 10k) is a dual inhibitor targeting α-glucosidase and α-amylase with IC50 of 34.52 nM and 24.62 nM, respectively. α-Amylase/α-Glucosidase-IN-12 is an inhibitor designed based on triazolo[4,3-b][1,2,4]triazine and has the potential to be used in diabetes research .
|
-
- HY-N9083
-
|
|
Others
|
Others
|
|
8α-Hydroxy-α-gurjunene is a Flavonoids product that can be isolated from the aerial parts of Sophora tomentosa L. .
|
-
- HY-N9960R
-
|
α-IPM (Standard)
|
Others
|
Others
|
|
α-Isopropylmalate (Standard) is the analytical standard of α-Isopropylmalate. This product is intended for research and analytical applications. α-Isopropylmalate (α-IPM) is the leucine biosynthetic precursor in Yeast .
|
-
- HY-129953S
-
-
- HY-119418
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
Desketoraloxifene is an estrogen receptors alpha (ERα) activator at an AP-1 site. Desketoraloxifene can be used for the research of osteoporosis and breast cancer .
|
-
- HY-W087904
-
|
α-D-Lactose hydrate
|
Endogenous Metabolite
|
Others
|
|
α-Lactose (hydrate) (α-D-Lactose (hydrate)) is the principal carbohydrate in the milk of most mammals. α-Lactose (hydrate) consists of glucose and galactose and exists in the form of two anomers, α and β. α-Lactose (hydrate) has many uses in the food and pharmaceutical industries, such as a free-flowing or agglomerating agent, a diluent for pigments, flavors, or enzymes .
|
-
- HY-129953B
-
|
15-epi PGF2α; 15(R)-PGF2α
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
15(R)-Prostaglandin F2α is the isomer of 9α,11β-Prostaglandin F2α (HY-129953). 9α,11β-Prostaglandin F2α is an endogenous metabolite present in Urine that can be used for the research of Asthma .
|
-
- HY-N8847
-
|
Alpha-Ionone
|
Hippo (MST)
YAP
|
Cancer
|
|
α-Ionone (alpha-Ionone) is an activator of the olfactory receptor OR10A6. α-Ionone induces apoptosis by activating OR10A6 and increasing the phosphorylation of the LATS-YAP-TAZ signaling axis in the Hippo pathway. α-Ionone can inhibit tumor formation both in vivo and in vitro .
|
-
- HY-121615
-
|
Alpha-Phellandrene
|
Fungal
|
Infection
|
|
α-Phellandrene (alpha-Phellandrene) has antifungal activity. α-Phellandrene significantly inhibits the hyphal growth of P. cyclopium, destroys their cell membrane integrity and causes leakage of cellular components .
|
-
- HY-N0683
-
-
- HY-133890A
-
|
T-α-MCA sodium
|
Endogenous Metabolite
FXR
|
Others
|
|
Tauro-α-muricholic acid (T-α-MCA) sodium is a FXR (Farnesoid X receptor) antagonist (IC50=28μM). Tauro-α-muricholic acid sodium is also a endogenous metabolite that can be found in cecal .
|
-
- HY-133890
-
|
T-α-MCA
|
Endogenous Metabolite
FXR
|
Cardiovascular Disease
Others
Metabolic Disease
|
|
Tauro-alpha-muricholic acid (T-alpha-MCA) is a bile acid that belongs to a class of compounds that are synthesized in the liver and play an important role in the digestive process. Tauro-α-muricholic acid activates Farni X receptors (FXR) which are involved in the regulation of bile acid synthesis, metabolism and transport. Tauro-alpha-muricholic acid can be used in the study of metabolic syndrome and cardiovascular disease .
|
-
- HY-123076
-
|
PFN-α
|
MDM-2/p53
|
Neurological Disease
|
|
Pifithrin-α, p-Nitro, Cyclic (PFN-α) is cell-permeable and active-form p53 inhibitor. Pifithrin-α, p-Nitro, Cyclic is one order magnitude more active than Pifithrin-α in protecting cortical neurons exposed to Etoposide (ED50=30 nM). Pifithrin-α, p-Nitro, Cyclic behaves as a p53 posttranscriptional activity inhibitor. Pifithrin-α, p-Nitro, Cyclic do not prevent p53 phosphorylation on the S15 residue .
|
-
- HY-N1720
-
|
|
Others
|
Others
|
|
2α,3α,24-Trihydroxyolean-12-en-28-oic acid (compound 5) is a terpenoid that is isolated from the branches and leaves of Pyrus pashia. 2α,3α,24-Trihydroxyolean-12-en-28-oic acid shows cytotoxic activity .
|
-
- HY-123712
-
-
- HY-N11598
-
|
|
Others
|
Metabolic Disease
|
|
α-GLU stands for α-glucosidase. α-GLU hydrolyzes starch and disaccharides via targeting to terminal, non-reducing (1→4)-linked α-D-glucose residues to produce α-glucose. α-GLU is substrate selective .
|
-
- HY-P3976
-
|
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine is a blood pressure lowering peptide containing 4 amino acids. Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine is an angiotensin-converting Enzyme (ACE) inhibitor. Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine can be used in research of high blood pressure .
|
-
![Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine](//file.medchemexpress.com/product_pic/hy-p3976.gif)
- HY-E70064
-
|
|
Endogenous Metabolite
|
Others
|
|
alpha-1,3-Fucosyltransferase (α1,3FucT) catalyzes the transfer of L-fucose moiety from guanosine diphosphate-beta-L-fucose (GDP-Fuc) to acceptor sugars. alpha-1,3-Fucosyltransferase (α1,3FucT) is often used in biochemical studies, and it can be used to form fucoglycoconjugates .
|
-
- HY-129953
-
-
- HY-W039849
-
|
Ethyl α-thioglucopyranoside
|
Biochemical Assay Reagents
|
Others
|
|
Ethyl-α-D-thioglucopyranoside (Ethyl α-Thioglucopyranoside) is a glycoside present in sake, Japanese rice wine. Ethyl-α-D-thioglucopyranoside is a glycosyl donor .
|
-
- HY-10019
-
|
CP 526555
|
nAChR
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .
|
-
- HY-10020
-
|
CP 526555 hydrochloride
|
nAChR
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .
|
-
- HY-10021
-
|
CP 526555-18
|
nAChR
ERK
p38 MAPK
|
Others
Neurological Disease
Cancer
|
|
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .
|
-
- HY-10019A
-
|
CP 526555 dihydrochloride
|
nAChR
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .
|
-
- HY-129764
-
|
PGF3α
|
P-glycoprotein
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Prostaglandin F3α (PGF3α) is an eicosapentaenoic acid (EPA)-derived bioactive lipid mediator that has anti-cancer and anti-inflammatory effects. Prostaglandin F3α is a substrate of ABCC4 with a Km of 12.1 μM. Prostaglandin F3α can be used for the research of diabetes .
|
-
- HY-E70059
-
|
|
Glucosylceramide Synthase (GCS)
|
Cancer
|
|
alpha-1,2-Fucosyltransferase (α1,2FucT), i.e., alpha 1, 2-fucosyltransferase, is often used in biochemical studies. alpha-1,2-Fucosyltransferase is a rate-limiting enzyme, can catalyze the synthesis of Lewis y (a cell membrane-associated carbohydrate antigen) .
|
-
- HY-W142080
-
-
- HY-P2707
-
|
α-DTX
|
Sodium Channel
Potassium Channel
|
Others
|
|
α-Dendrotoxin (α-DTX) is a small molecule peptide neurotoxin isolated from the venom of the African green mamba snake (Dendroaspis angusticeps). α-Dendrotoxin is also a KV1.1, KV1.2, KV1.6 and ASIC channel blocker. α-Dendrotoxin blocks potassium channels, lowers the threshold of neuronal action potentials, and increases the frequency of action potentials, thereby enhancing neuronal excitability. α-Dendrotoxin can be used in neurotoxicology research .
|
-
- HY-167584S
-
-
- HY-170045
-
-
- HY-101337
-
-
- HY-116549
-
|
PGF2α alcohol
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
Prostaglandin F2α alcohol (PGF2α alcohol) is an analog of PGF2α. Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist .
|
-
- HY-170050
-
-
- HY-E70053
-
|
Alpha 1,3GT
|
Endogenous Metabolite
|
Metabolic Disease
|
|
alpha-1,3-Galactosyltransferase (GTB) (alpha 1,3GT) catalyzes the synthesis of the xenoantigen or α-galactose (α-Gal) epitope. alpha-1,3-Galactosyltransferase (GTB) transfers galactose from UDP-Gal to type 1 or type 2, αFuc1→2βGal-R (H)-terminating acceptors .
|
-
- HY-W587800
-
-
- HY-127144
-
|
α-Dihydrosaxitoxin
|
Drug Derivative
|
Neurological Disease
|
|
α-Saxitoxinol is an epimer of Dihydtosaxitoxin and a derivative of saxitoxin. α-Saxitoxinol represents approximately 3.7% of the biological activity of Saxitoxin (a neurotoxin) .
|
-
- HY-123489
-
|
THDOC
|
GABA Receptor
|
Neurological Disease
|
|
3α,21-Dihydroxy-5α-pregnan-20-one (THDOC), an endogenous neurosteroid, is a positive modulator of GABAA receptors. 3α,21-Dihydroxy-5α-pregnan-20-one potentiates neuronal response to low concentrations of GABA at α4β1δ GABAA receptors in vitro.
|
-
- HY-14190
-
|
R-411 free base
|
Integrin
|
Inflammation/Immunology
|
|
Valategrast (R-411 free base) is a potent and orally active integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment .
|
-
- HY-W677042
-
|
5α-Androst-16-en-3α-ol
|
GABA Receptor
|
Neurological Disease
|
|
α-Androstenol (5α-Androst-16-en-3α-ol) is a steroid pheromone that has been found in boar testes and human male axillary sweat. α-Androstenol is also a positive modulator of GABAA receptors, which enhances GABA-activated currents in primary mouse cerebellar granule cells (EC50=0.4 μM). α-Androstenol decreases immobility time in the forced swim test and increases time spent in the open arms of the elevated plus maze in mice. α-Androstenol protects against seizures induced by Pentylenetetrazole or electroshock with anxiolytic-like activity in mice .
|
-
- HY-149331
-
|
|
TNF Receptor
Caspase
NF-κB
|
Inflammation/Immunology
|
|
TNF-α-IN-11 (Compound 10) is a TNF-α inhibitor with a KD value of 12.06 μM. TNF-α-IN-11 binds to TNF-α and blocks the activation of TNF-α-trigged caspase and NF-κB signaling pathway. TNF-α-IN-11 inhibits the phosphorylation of IκBα, as well as the nuclear translocation of NF κB p65. TNF-α-IN-11 can be used for research of TNF-α-mediated autoimmune diseases .
|
-
- HY-W020044
-
|
DL-α-Tocopherol
|
Ferroptosis
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
DL-alpha-Tocopherol is a synthetic vitamin E, with antioxidation effect. DL-alpha-Tocopherol protects human skin fibroblasts against the cytotoxic effect of UVB .
|
-
- HY-160436
-
-
- HY-P2802
-
|
α-D-Glucosidase, Yeast
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase, Yeast (α-D-Glucosidase, Yeast), a carbohydrate hydrolyzing enzyme, catalyzes the liberation of α-glucose from the non-reducing end of the substrate. α-Glucosidase can facilitate the absorption of glucose by the small intestine. Inhibition of α-Glucosidase is an effective management of non-insulin-dependent diabetes mellitus (NIDDM) .
|
-
- HY-W127431
-
|
5α-Cholanic acid-3α-ol-6-one 3-acetate methyl ester
|
Biochemical Assay Reagents
|
Others
|
|
Methyl (3α,5α)-3-(acetyloxy)-6-oxocholan-24-oate is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-W039911
-
|
PNP-Alpha-D-Gal; PNP-α-D-Gal
|
Biochemical Assay Reagents
|
Others
|
|
4-Nitrophenyl α-D-galactopyranoside (PNP-alpha-D-Gal) is an artificial substrate of 4-nitrophenyl (pNP) glycopyranoside for detecting α-galactosidase activity. The amount of released pNP is significantly increased when 4-Nitrophenyl α-D-galactopyranoside is used as substrates .
|
-
- HY-P1264
-
|
|
nAChR
|
Neurological Disease
|
|
α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs). α-Bungarotoxin, a selective α7 receptor blocker, blocks α7 currents with an IC50 of 1.6 nM and has no effects on α3β4 currents at concentrations up to 3 μM .
|
-
- HY-116757
-
-
- HY-118710
-
-
- HY-N0683A
-
-
- HY-102022
-
|
α-GalCer; KRN7000
|
Transmembrane Glycoprotein
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide plus CD1d binds the NKT cell TCR (T cell antigen receptor) .
|
-
- HY-N2018
-
|
α-D-Xylopyranose
|
Endogenous Metabolite
|
Metabolic Disease
|
|
α-D-Xylose (α-D-Xylopyranose) is a basic component of the five-carbon fraction of biomass and a precursor of hemicellulose. α-D-Xylose participates in a variety of enzyme-catalyzed reactions, which in turn participate in a variety of metabolic pathways. In addition, α-D-Xylose is also used in tanning, dyeing and as a diabetic food .
|
-
- HY-Y0149S
-
-
- HY-E70104
-
|
α-L-Rhamnosidase
|
Others
|
Others
|
|
α-Rhamnosidase is a glycoside hydrolase. α-Rhamnosidase is able to finish the enzymatic de-glycosylation of many nature flavone glycosides .
|
-
- HY-P2901
-
|
3α-HSD
|
Endogenous Metabolite
|
Endocrinology
|
|
3α-Hydroxysteroid Dehydrogenase, Microorganism (3α-HSD) is an enzyme encoded by the AKR1C4 gene, which can catalyze the conversion of 3-ketosteroids into 3α-hydroxy compounds. 3α-Hydroxysteroid dehydrogenase plays an important role in the inactivation of androgen DHT, and can convert DHT into 3α-androstanediol with weak androgen activity, which can be used in the research of hirsutism .
|
-
- HY-134420
-
-
- HY-164293
-
-
- HY-P5053
-
|
|
Radionuclide-Drug Conjugates (RDCs)
Integrin
|
Cancer
|
|
Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α?β? selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
|
-
- HY-N9699
-
|
|
NF-κB
|
Inflammation/Immunology
|
|
8α-Hydroxyhirsutinolide is a sesquiterpene lactone. 8α-Hydroxyhirsutinolide inhibits TNF-α-induced NF-κB activity (IC50: 1.9 μM) and NO production. 8α-Hydroxyhirsutinolide can be isolated from Vernonia cinerea .
|
-
- HY-N0700
-
|
α-Asarone; trans-Asarone
|
GABA Receptor
|
Neurological Disease
|
|
alpha-Asarone (α-Asarone) is one of the main psychoactive compounds, and possesses an antidepressant-like activity in mice.
|
-
- HY-N1820
-
-
- HY-N8745
-
![Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine](http://file.medchemexpress.com/product_pic/hy-p3976.gif)
